Study of the burden on patients with chronic obstructive pulmonary disease

International Journal of Clinical Practice

Volumn 63, Issue 1, 2009, Pages 87-97

  Izquierdo, J L ^a   Barcina, C ^b   Jimenez J ^b   Munoz M ^b   Leal, M ^b  

^a HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID;

ADULT; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; CULTURAL FACTOR; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING HABIT; SOCIOECONOMICS;

EID: 57649181429     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01936.x     Document Type: Article

References (32)

1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004 364 : 613 20.
2. Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC. The burden and impact of COPD in Asia and Africa. Int J Tuberc Lung Dis 2004 8 : 2 14.
3. Mannino DM. Epidemiology and global impact of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005 26 : 204 10.
4. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006 28 : 523 32.
5. Sobradillo-Peña S, Miravitlles M, Gabriel R et al. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 2000 118 : 981 9.
6. Izquierdo JL, De Miguel J. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease. COPD 2004 1 : 215 23.
7. Miravitlles M. Evaluación económica en la EPOC. Arch Bronconeumol 2001 37 (Suppl. 2 38.
8. Izquierdo JL. The burden of COPD in Spain: Results from the confronting survey. Respir Med 2003 97 : S61 9.
9. Weiss ST, DeMeo DL, Postma DS. COPD: problems in diagnosis and measurement. Eur Respir J 2003 21 (Suppl. 41 4s 12s.
10. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000 117 : 54S 7S.
11. Hajiro T, Nishimura K, Tsukino M, Ikeda A, Oga T. Stages of disease severity and factors that affect the health status of patients with chronic obstructive pulmonary disease. Respir Med 2000 94 : 841 6.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of chronic airflow limitation - the St George Respiratory Questionnaire. Am Rev Respir Dis 1992 145 : 1321 7.
13. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987 42 : 773 8.
14. Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the Quality of life for Respiratory Illness questionnaire (QOL-RIQ): a disease-specific quality of life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med 1997 91 : 297 309.
15. van der Molen T, Willense BWM, Schokker S, ten Hacken NHT, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes 2003 1 : 13.
16. Kocks JWH, Tuinenga MG, Uil SM, van den Berg JWK, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006 7 : 62.
17. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003 124 : 459 67.
18. Wouters EF. Management of severe COPD. Lancet 2004 364 : 883 95.
19. Connors AF Jr., Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996 154 : 959 67. Erratum in: Am J Respir Crit Care Med 1997 Jan; 155(1): 386.
20. Masa JF et al. Costs of chronic obstructive pulmonary disease in Spain. Estimation from a population-based study. Arch Bronconeumol 2004 40 : 72 9.
21. Fan VS et al. Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest 2002 122 : 429 36.
22. Marín Trigo JM. Manifestaciones clínicas: la disnea y su importancia en el paciente con EPOC. Arch Bronconeumol 2001 37 (Suppl. 2 8 13.
23. Marín JM, Carrizo SJ, Gascón M, Sánchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 163 : 1395 9.
24. De Miguel Díez J, Izquierdo Alonso JL, Molina París J, Bellón cano JM, Rodríguez González Moro JM, De Lucas Ramos P. Factores determinantes de la prescripción farmacológica en los pacientes con EPOC estable. Arch Bronconeumol 2005 41 : 63 70.
25. Efthimiou J, Fleming J, Gomes C, Spiro SG. The effect of supplementary oral nutrition in poorly nourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1998 137 : 1075 82.
26. Sahebjami H, Doers JT, Render ML, Bond TL. Anthropometric and pulmonary function test profile of outpatients with stable chronic obstructive pulmonary disease. Am J Med 1993 94 : 469 74.
27. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 350 : 1005 12.
28. Schols AMWJ, Soeters PB, Dingemans MC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am J Respir Crit Care Med 1993 147 : 1151 6.
29. Sahebjami H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000 161 : 886 90.
30. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramírez-Sarmiento A, Antó JM, Gea J. Wood smoke exposure and risk of chronic obstructive pulmonary disease. Eur Respir J 2006 27 : 542 6.
31. Menezes AM, Hallal PC, Perez-Padilla R et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007 30 : 1180 5.
32. Birring SS, Brightling ChE, Bradding P et al. Clinical, radiologic, and induced sputum features of chronic obstructive pulmonary disease in nonsmokers: a descriptive study. Am J Respir Crit Care Med 2002 166 : 1078 83.